Abstract
Recent clinical and experimental studies have identified the importance of ‘neurohormones’ as biological mediators and/or modifiers of left ventricular remodeling and disease progression in the failing heart. This insight has, in turn, provided the rationale basis for antagonizing the activation of neurohormonal systems (e.g. the renin angiotensin system and the adrenergic system) in the setting of heart failure. In addition to neurohormones, it has become apparent that another portfolio of biologically active molecules, termed cytokines, are expressed along with the neurohormones in the setting of heart failure. The current interest in understanding the role or pro-inflammatory cytokines, such as tumor necrosis factor (TNF), in heart failure relates to the observation that many aspects of the syndrome of heart failure can be explained by the (Table 1). Simply stated, when expressed at sufficiently high concentrations, TNF mimics some aspects of the so-called heart failure phenotype, including (but not limited to) progressive left ventricular (LV) dysfunction, pulmonary edema, LV remodeling, fetal gene expression and cardiomyopathy. Thus the elaboration of TNF, much like the elaboration of neurohormones, may represent a biological mechanism that is responsible for producing symptoms in patients with heart failure. In the present discussion, we will review several important areas that are directly relevant to the role of TNF as a mediator of disease progression in the failing heart, including a brief overview of the biology of TNF, followed by a discussion of the deleterious effects of TNF on LV remodeling effects, and finally a review of the clinical studies that link TNF production to disease progression in heart failure.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Carswell EA, Old LJ, Kassel RL, et al. An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666–3670.
Old L.T. Tumor necrosis factor (TNF). Science 1985;230:630–632.
Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-a provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997;95:1247–1252.
Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303–2312.
Gulick TS, Chung MK, Pieper SJ, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte ß-adrenergic responsiveness. Proc Natl Acad Sci USA 1989;86:6753–6757.
Giroir BP, Johnson JH, Brown T, et al. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992;90:693–698.
Kapadia S, Lee JR, Torre-Amione G, et al. Tumor necrosis factor gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995;96:1042–1052.
Kapadia S, Oral H, Lee J, et al. Hemodynamic regulation of tumor necrosis factor-a gene and protein expression in adult feline myocardium. Circ Res 1997;81:187–195.
Torre-Amione G, Kapadia S, Lee J, et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487–1493.
Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-a and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704–711.
Krown KA, Yasui K, Brooker MJ, et al. TNFa receptor expression in rat cardiac myocytes: TNFa inhibition of L-type Cat+ current and Cat+ transients. FEBS Lett 1995;376:24–30.
Oral H, Dorn GW, II, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-a in the adult mammalian cardiac myocyte. J Biol Chem 1997;272:4836–4842.
Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854–2865.
Nakano M, Knowlton AA, Dibbs Z, et al. Tumor necrosis factor-a confers resistance to injury induced by hypoxic injury in the adult mammalian cardiac myocyte. Circulation 1998;97:1392–1400.
Linzbach AJ. Heart Failure from the Point of View of Quantitative Anatomy. Am J Cardiol 1960;69:370–382.
Cohn JN. Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition. Circulation 1995;91:2504–2507.
Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-alpha. Cire Res 1997;81:627–635.
Kubota T, Bounoutas GS, Miyagishima M, et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000; 101(21):2518–2525.
Bozkurt B, Kribbs S, Clubb Jr FJ, et al. Patho physiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97:1382–1391.
Mann DL. Cytokines as mediators of disease progression in the failing heart. In: Hosenpud JD, Greenberg BH, eds. Congestive Heart Failure. Philadelphia: Lippincott Williams & Wilkins, 1999:213–232.
Semp H, Peterson J, Tavernier J, et al. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987;262:8390–8394.
Begum N, Ragolia L. Effect of tumor necrosis factor-a on insulin action in cultured rat skeletal muscle cells. Endocrinology 1996;137:2441–2446.
Peraldi P, Hotamisligil GS, Buurman WA, et al. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase.J Biol Chem1996; 271:13018–13022.
Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43–52.
Kjekshus J, Mjos O. Effects of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J Clin Invest 1994;51:1767–1776.
Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280–287.
Pagani FD, Basker LS, Hsi C, et al. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-a in conscious dogs. J Clin Invest 1992;90:389–398.
Bryant D, Becker L, Richardson J, et al. Cardiac Failure in transgenic mice with myocardial expression of tumor necrosis factor-a (TNF). Circulation 1998; 97:1375–1381.
Sciavolino PJ, Lee TH, Vilcek J. Interferon-ß induces metalloproteinase mRNA expression in human fibroblasts. J Biol Chem 1994;269:21627–21634.
Van der Zee E, Everts V, Beertsen W. Cytokines modulate routes of collagen breakdown: review with special emphasis of collagen degradation in the periodontium and the burst hypothesis of periodontal disease progression. J Clin Periodontol 1997; 24:297–305.
Rawdanowicz TJ, Hampton AL, Nagase H, et al. Matrix metalloproteinase production by cultured human endometrial stromal cells: identification of interstitial collagenase, gelatinase-A, genatinase-B, and stromelysin-1 and their differential regulation by interleukin-la and their differential regulation by interleukin-la and tumor necrosis factor-a. J Clin Endocrinol Metab 1994;79:530–536.
Weber KT, Pick R, Janicki JS, et al. Inadequate collagen tethers in dilated cardiopathy. Am Heart J 1998;116:1641–1646.
Factor SM, Robinson TF. Comparative connective tissue structure: function relationships in biological pumps. Lab Invest 1988;58:150–156.
Weber KT. Cardiac Intersitium in Health and Disease: The Fibrillar Collagen Networks. J Am Coll Cardiol 1989;13(7):1637–1652.
Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;223:236–241.
McMurray J, Abdullah I, Dargie HJ, et al. Increased concentrations of tumor necrosis factor in ’cachetic’ patients with severe chronic heart failure. Br Heart J 1991;66:356–358.
Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050–1053.
Torre-Amione G, Kapadia S, Benedict CR, et al. Pro-inflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201–1206.
Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964–971.
Bachetti T, Comini L, Agnoletti L, et al. Attivazione e ruolo del fattore di necrosi tumorale alfa nello scompenso cardiaco congestizio. Cardiologia 1996;41:343–347.
Doyama K, Fujiwara H, Fukumoto M, et al. Tumour necrosis factor is expressed in cardiac tissues of patients with heart failure. Int J Cardiol 1996; 54(3):217–225.
Habib FM, Springall DR, Davies GJ, et al. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347:1151–1155.
Bozkurt B, Torre-Amione G, Deswal A, Soran OZ, Whitmore J, Warren M, Mann DL. Regression of left ventricular remodeling in chronic heart failure after treatment with enbrel (Etanercept, p75 TNF receptor Fc fusion protein). Circulation 100:I, 105. 1999. Ref Type: Generic.
Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994;90:12–16.
Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure. Circulation 1995;92:1479–1486.
Anker SD, Volterrnani M, Egerer KR, et al. TNF-a as predictor of peak leg blood flow in chronic heart failure. Q J Med 1998;91:199–203.
Matsumori A, Yamada T, Suzuki H, et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72;561–566.
Sindhwani R, Yuen J, Hirsch H, Tegguy A, Galvao M, Levato P, LeJemtel TH. Reversal of low flow state attenuates immune activation in severe decompensated congestive heart failure. Circulation 1993; 88:1–255.
Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391–398.
Niebauer J, Volk H-D, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 99 Á.D.;353:1838–1842.
Dibbs Z, Thornby J, White BG, et al. Natural Variability of Circulating Levels of Cytokines and Cytokine Receptors in Patients with Heart Failure: Implications for Clinical Trials. J Am Coll Cardiol 1999; 33:1935–1942.
Oddis CV, Simmons RL, Hattler BG, et al. cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes. Am J Physiol 1995;269:H2044–H2050.
Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000;101(20):2338–2341.
Prabhu SD, Chandrasekar B, Murray DR, et al. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000; 101(17):2103–2109.
Kapadia S, Dibbs Z, Kurrelmeyer K, et al. The role of cytokines in the failing human heart. In: Crawford M, ed. Cardiology Clinics. Philadelphia: W.B. Saunders, 1998:645–656.
Nakano M, Knowlton AA, Yokoyama T, et al. Tumor necrosis factor-a induced expression of heat shock protein 72 in adult feline cardiac myocytes. Am J Ph ysi of 1996; 270:H1231—H1239.
Kurrelmeyer K, Michael L, Baumgarte G, et al. Endogenous myocardial tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a mutine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000;290:5456–5461.
Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Cardiac Failure 1996;2:243–249.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Mann, D.L. (2001). Recent Insights into the Role of Tumor Necrosis Factor in the Failing Heart. In: Mann, D.L. (eds) The Role of Inflammatory Mediators in the Failing Heart. Developments in Cardiovascular Medicine, vol 236. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1449-7_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1449-7_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5559-5
Online ISBN: 978-1-4615-1449-7
eBook Packages: Springer Book Archive